Skip to main content
Premium Trial:

Request an Annual Quote

New Oncology to Perform Cancer MDx for University Hospital Oslo

NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration with the University Hospital Oslo aimed at guiding treatment of patients with targeted cancer therapies.

Financial details of the agreement weren't disclosed, but New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, said that under the collaboration it will use its next-gen sequencing diagnostic platform, Neo, to identify alterations in cancer-related genes that predict a patient's response or resistance to targeted therapies.

New Oncology's pan-cancer diagnostic, NEOplus, uses next-gen sequencing and a proprietary computational biology strategy to identify mutations in more than 80 oncogenes, tumor suppressors, and microsatellite DNA from a single FFPE sample, according to the company's website.

The test detects and interprets therapeutically relevant genetic alterations, including mutations, amplifications, insertions and deletions, as well as novel and known translocations, with a turnaround time of 10-15 days.

New Oncology recently announced similar agreements with the National Cancer Centre Singapore and the Gustave Roussy Cancer Campus in Paris